GlassScriptPhysician profile
Hilmer Octavio Negrete
NPI 1215911151
$4,210.37
in general payments reported to CMS, 2019-2025
32 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $217 · 2021: $276 · 2022: $619 · 2023: $897 · 2024: $824 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $516.11 | 2020-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $356.34 | 2019-2024 | Farxiga |
| Calliditas Therapeutics US INC. | $321.37 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $318.87 | 2019-2023 | Veltassa, Korsuva |
| Nxstage Medical, INC. | $291.02 | 2019-2025 | Liberty Select Cycler, Nxstage System One, Pureflow Sl |
| Novartis Pharmaceuticals Corporation | $260.12 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $218.92 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $215.66 | 2022-2024 | |
| Baxter Healthcare | $180.73 | 2019-2020 | |
| Vantive US Healthcare LLC | $165.54 | 2025 | Renal - Pd |
| Bard Peripheral Vascular, INC. | $148.71 | 2019 | |
| Genzyme Corporation | $133.15 | 2019-2023 | |
| Horizon Therapeutics Plc | $123.28 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $113.79 | 2021-2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $108.95 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $96.77 | 2019-2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $96.71 | 2021-2025 | Jynarque |
| Gilead Sciences, INC. | $83.33 | 2023 | Veklury |
| Ardelyx, INC. | $74.06 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $64.20 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $55.53 | 2020-2021 | |
| Novo Nordisk INC | $36.54 | 2023-2024 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $33.29 | 2019 | |
| Glaxosmithkline, LLC. | $31.71 | 2021-2022 | |
| Biomerieux INC | $27.27 | 2024 | Vidas Nephrocheck |
| Alexion Pharmaceuticals, INC. | $25.65 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $23.74 | 2023 | Oxlumo |
| Cycle Pharmaceuticals INC | $20.38 | 2025 | Venxxiva |
| Scpharmaceuticals INC. | $20.03 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.23 | 2024 | |
| Fresenius USA Marketing, INC. | $18.49 | 2024 | Velphoro |
| Janssen Pharmaceuticals, INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilmer Negrete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.